{"id":6567,"date":"2005-11-28T15:34:00","date_gmt":"2005-11-28T15:34:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=6567"},"modified":"2022-01-25T14:37:25","modified_gmt":"2022-01-25T14:37:25","slug":"open-label-trial-of-granulocyte-apheresis-suggests-therapeutic-efficacy-in-chronically-active-steroid-refractory-ulcerativecolitis","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/open-label-trial-of-granulocyte-apheresis-suggests-therapeutic-efficacy-in-chronically-active-steroid-refractory-ulcerativecolitis\/","title":{"rendered":"Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Wolfgang Kruis, Axel Dignass, Elisabeth Steinhagen-Thiessen, Julia Morgenstern, Joachim M\u00f6ssner,<br>Stephan Schreiber, Maurizio Vecchi, Alberto Malesci, Max Reinshagen, Robert L\u00f6fberg<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>World J Gastroenterol 2005;11(44):7001-7006 <\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>AIM: To study the efficacy, safety, and feasibility of a granulocyte adsorptive type apheresis system for the treatment of patients with chronically active ulcerative colitis despite standard therapy. METHODS: An open label multicenter study was carried out in 39 patients with active ulcerative colitis (CAI 6-8) despite continuous use of steroids (a minimum total dose of 400 mg prednisone within the last 4 wk). Patients received a total of five aphereses using a granulocyte adsorptive technique (Adacolumn\u00ae, Otsuka Pharmaceutical Europe, UK). Assessments at wk 6 and during follow-up until 4 mo comprised clinical (CAI) and endoscopic (EI) activity index, histology, quality of life (IBDQ), and laboratory tests. RESULTS: Thirty-five out of thirty-nine patients were qualified for intent-to-treat analysis. After the apheresis treatment at wk 6, 13\/35 (37.1%) patients achieved clinical remission and 10\/35 (28.6%) patients had endoscopic remission (CAI&lt;4, EI&lt;4). Quality of life (IBDQ) increased significantly (24 points, P &lt;0.01) at wk 6. Apheresis could be performed in all but one patient. Aphereses were well tolerated, only one patient experienced anemia. CONCLUSION: In patients with steroid refractory ulcerative colitis, five aphereses with a granulocyte\/ monocyte depleting filter show potential short-term efficacy. Tolerability and technical feasibility of the procedure are excellent.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/www.wjgnet.com\/1007-9327\/full\/v11\/i44\/7001.htm\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.wjgnet.com\/1007-9327\/full\/v11\/i44\/7001.htm<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Wolfgang Kruis, Axel Dignass, Elisabeth Steinhagen-Thiessen, Julia Morgenstern, Joachim M\u00f6ssner,Stephan Schreiber, Maurizio Vecchi, Alberto Malesci, Max Reinshagen, Robert L\u00f6fberg World J Gastroenterol 2005;11(44):7001-7006 AIM: To study the efficacy, safety, and feasibility of a granulocyte adsorptive type apheresis system for the treatment of patients with chronically active ulcerative colitis despite standard therapy. METHODS: An open label [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[330,157,424,96,135,306],"class_list":["post-6567","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-clinical-trial","scientific_tags-efficacy","scientific_tags-gma","scientific_tags-open-label","scientific_tags-steroid-refractory","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/open-label-trial-of-granulocyte-apheresis-suggests-therapeutic-efficacy-in-chronically-active-steroid-refractory-ulcerativecolitis\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Wolfgang Kruis, Axel Dignass, Elisabeth Steinhagen-Thiessen, Julia Morgenstern, Joachim M\u00f6ssner,Stephan Schreiber, Maurizio Vecchi, Alberto Malesci, Max Reinshagen, Robert L\u00f6fberg World J Gastroenterol 2005;11(44):7001-7006 AIM: To study the efficacy, safety, and feasibility of a granulocyte adsorptive type apheresis system for the treatment of patients with chronically active ulcerative colitis despite standard therapy. METHODS: An open label [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/open-label-trial-of-granulocyte-apheresis-suggests-therapeutic-efficacy-in-chronically-active-steroid-refractory-ulcerativecolitis\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-25T14:37:25+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/open-label-trial-of-granulocyte-apheresis-suggests-therapeutic-efficacy-in-chronically-active-steroid-refractory-ulcerativecolitis\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/open-label-trial-of-granulocyte-apheresis-suggests-therapeutic-efficacy-in-chronically-active-steroid-refractory-ulcerativecolitis\/\",\"name\":\"Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2005-11-28T15:34:00+00:00\",\"dateModified\":\"2022-01-25T14:37:25+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/open-label-trial-of-granulocyte-apheresis-suggests-therapeutic-efficacy-in-chronically-active-steroid-refractory-ulcerativecolitis\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/open-label-trial-of-granulocyte-apheresis-suggests-therapeutic-efficacy-in-chronically-active-steroid-refractory-ulcerativecolitis\/","og_locale":"es_ES","og_type":"article","og_title":"Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis - Adacyte","og_description":"Wolfgang Kruis, Axel Dignass, Elisabeth Steinhagen-Thiessen, Julia Morgenstern, Joachim M\u00f6ssner,Stephan Schreiber, Maurizio Vecchi, Alberto Malesci, Max Reinshagen, Robert L\u00f6fberg World J Gastroenterol 2005;11(44):7001-7006 AIM: To study the efficacy, safety, and feasibility of a granulocyte adsorptive type apheresis system for the treatment of patients with chronically active ulcerative colitis despite standard therapy. METHODS: An open label [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/open-label-trial-of-granulocyte-apheresis-suggests-therapeutic-efficacy-in-chronically-active-steroid-refractory-ulcerativecolitis\/","og_site_name":"Adacyte","article_modified_time":"2022-01-25T14:37:25+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/open-label-trial-of-granulocyte-apheresis-suggests-therapeutic-efficacy-in-chronically-active-steroid-refractory-ulcerativecolitis\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/open-label-trial-of-granulocyte-apheresis-suggests-therapeutic-efficacy-in-chronically-active-steroid-refractory-ulcerativecolitis\/","name":"Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2005-11-28T15:34:00+00:00","dateModified":"2022-01-25T14:37:25+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/open-label-trial-of-granulocyte-apheresis-suggests-therapeutic-efficacy-in-chronically-active-steroid-refractory-ulcerativecolitis\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/6567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=6567"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=6567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}